MedTrace Logo

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

NCT03509545 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-24

No results posted yet for this study

Summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Conditions

  • Body Weight Changes

Interventions

DRUG

CHF Patients: ER Torsemide 40 mg

ER Torsemide 40mg given once daily to CHF patients

DRUG

CHF Patients: Furosemide 40 mg

Stable CHF patients taking twice-daily 40 mg Furosemide

Sponsors & Collaborators

  • Sarfez Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Anil K, MD · Syngene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509545 on ClinicalTrials.gov